Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologi...
Guardado en:
Autores principales: | Parisi S, Finelli C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/13fa4193da1b4fd292ba8f964c3b6833 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
DIAGNOSTIC APPLICATION AND CLINICAL SIGNIFICANCE OF FCM WELLS SCORING SYSTEM IN MYELODYSPLASTIC SYNDROMES
por: Reyhan Aliyeva, et al.
Publicado: (2021) -
Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
por: Bodiford A, et al.
Publicado: (2015) -
Reticulocyte Hemoglobin Equivalent: Diagnostic Performance in Assessment of Iron Deficiency in Patients with Hypothyroidism
por: Wardah Aslam, et al.
Publicado: (2021) -
Azacytidine Treatment for VEXAS Syndrome
por: Marc H. G. P. Raaijmakers, et al.
Publicado: (2021) -
IS METHYLATION STATUS SUBGROUPING REALLY A STRONG PROGNOSTIC FACTOR IN PEDIATRIC POSTERIOR FOSSA EPENDYMOMA?
por: Bahattin Tanrıkulu, et al.
Publicado: (2021)